Safety Evaluation of Gene Therapy Drug in the Treatment of Primary Hypertriglyceridemic Patients With Recurrent Pancreatitis | MicrobiomeTrials← Back to trialsNCT05860569
Safety Evaluation of Gene Therapy Drug in the Treatment of Primary Hypertriglyceridemic Patients With Recurrent Pancreatitis
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2024-09-20Est. Completion: 2026-12
Enrollment target: 7 participants Locations- Peking Union Medical College, Beijing, Beijing Municipality, China
Other microbiome trials you might be interested in
CardiovascularMetabolic DiseaseDyslipidemiasLipid DisorderHypertriglyceridemiaHeterozygous Familial Hypercholesterolemia (HeFH)Homozygous Familial Hypercholesterolemia (HoFH)Severe Hypertriglyceridemia (sHTG)Mixed HyperlipemiaHypercholesterolaemia
This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years…
Hialeah, United StatesEst. completion Jun 2027
Cardiovascular Kidney Metabolic Syndrome
The goal of this observational registry study is to learn about cardiovascular-kidney-metabolic syndrome, also called CK…
Multiple LocationsEst. completion Dec 31, 2027
Lipid Disorders
Background:
\- Genes are the instructions our body uses to function. Researchers can look for changes, or variants, in …
Bethesda, United StatesCompleted Sep 2, 2021